8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934


Date of Report (Date of earliest event reported)        July 7, 2005
                                                 -----------------------------

                              Amazon Biotech, Inc.
 -------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

             Utah                       000-26753                 87-041631
- --------------------------------------------------------------------------------
(State or other jurisdiction           (Commission             (IRS Employer
      of incorporation)                File Number)          Identification No.)

       43 West 33rd Street, Suite 405, New York,                   NY 10001
- --------------------------------------------------------------------------------
       (Address of principal executive offices)                   (Zip Code)

Registrant's telephone number, including area code:  (212) 695-3003

- --------------------------------------------------------------------------------
         (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2.below):

[ ]   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

[ ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

[ ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

[ ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))




Section 1 - Registrant's Business and Operations

Item 1.01   Entry into a Material Definitive Agreement.

      Not applicable

Item 1.02   Termination of a Material Definitive Agreement.

      Not applicable

Item 1.03   Bankruptcy or Receivership.

      Not applicable

Section 2 - Financial Information

Item 2.01   Completion of Acquisition or Disposition of Assets.

      Not applicable

Item 2.02   Results of Operations and Financial Condition.

      Not applicable

Item 2.03   Creation of a Direct Financial Obligation or an Obligation under an
            Off-Balance Sheet Arrangement of a Registrant.

      Not applicable

Item 2.04   Triggering Events That Accelerate or Increase a Direct Financial
            Obligation or an Obligation Under an Off-Balance Sheet Arrangement.

      Not applicable

Item 2.05   Costs Associated with Exit or Disposal Activities.

      Not applicable

Item 2.06   Material Impairments.

      Not applicable

Section 3 - Securities and Trading Markets

Item 3.01   Notice of Delisting or Failure to Satisfy a Continued Listing Rule
            or Standard: Transfer of Listing.

      Not applicable

Item 3.02   Unregistered Sales of Equity Securities.

      Not applicable

Item 3.03   Material Modification to Rights of Security Holders.

      Not applicable


                                       2


Section 4 - Matters Related to Accountants and Financial Statements

Item 4.01   Changes in Registrant's Certifying Accountant.

      Not applicable

Item 4.02   Non-Reliance on Previously Issued Financial Statements or a Related
            Audit Report or Completed Interim Review.

      Not applicable

Section 5 - Corporate Governance and Management

Item 5.01   Changes in Control of Registrant.

      Not applicable

Item 5.02   Departure of Directors or Principal Officers; Election of Directors;
            Appointment of Principal Officers.

      Simcha Edell, MBA was appointed as our Chief Financial Officer on July 7,
2005. Previously, Mr. Edell served as head of finance and business development
at Sightline Technologies Inc., a medical devices firm. During his tenure, he
assisted Sightline in it fundraising efforts, brought products to market and
developed strategic relationships.. Mr. Edell has also worked as a business
consultant in various fields, including healthcare. No employment agreement has
been entered into as of the date hereof.

Item 5.03   Amendments to Articles of Incorporation or Bylaws: Change in Fiscal
            Year.

      Not applicable

Item 5.04   Temporary Suspension of Trading Under Registrant's Employee Benefit
            Plans.

      Not applicable

Item 5.05   Amendments to the Registrant's Code of Ethics, or Waiver of a
            Provision of the Code of Ethics.

      Not applicable

Section 6 - [Reserved]

      Not applicable

Section 7 - Regulation FD

Item 7.01   Regulation FD Disclosure.

      Not applicable

Section 8 - Other Events

Item 8.01   Other Events.

      Not applicable


                                       3


Section 9 - Financial Statements and Exhibits

Item 9.01   Financial Statements and Exhibits.

      (a)   Financial Statements of Businesses Acquired.

            Not applicable.

      (b)   Pro Forma Financial Information.

            Not applicable.

      (c)   Exhibits.

            Exhibit
            Number       Description
            ------       -----------

            99.1         Press Release


                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                      AMAZON BIOTECH, INC.
                                      (Registrant)


Date: July 13, 2005                   By: /s/ Mechael Kanovsky, Ph.D.
                                           -------------------------------------
                                              Mechael Kanovsky, Ph.D., President


                                       4

EX-99.1

                                                                    Exhibit 99.1

Press Release

       Amazon Biotech, Inc. Announces the Appointment of Simcha Edell, MBA
                    as the Company's Chief Financial Officer

Thursday July 7, 1:11 pm ET

NEW YORK, July 7 /PRNewswire-FirstCall/ -- Amazon Biotech, Inc. (OTC Bulletin
Board: AMZB - News), a pharmaceutical company developing and producing a
potential immunomodulator drug, developed for use in the treatment of the HIV
virus, today announced that it has appointed Simcha Edell, MBA as the company's
Chief Financial Officer.

Simcha Edell earned his Bachelors of Commerce at the University of Toronto, and
his MBA from York University. He was head of finance and business development at
SightLine Technologies Inc., a hi-tech firm developing medical devices. During
his tenure, he assisted the company in its fundraising efforts, and brought
products to market. He was instrumental in gaining the interest of multinational
firms in the company's projects, and was successful in engaging a large U.S.
firm (Boston Scientific Corp.) as a strategic partner. Mr. Edell has also worked
as a business consultant in various fields, including healthcare.

Dr. Mechael Kanovsky, President of Amazon Biotech, Inc. said "With his vast
experience in business development and financing, I am confident that Mr. Edell
will help the Company raise capital and develop strategies to maximize the
company's potential and revenues".

About Amazon Biotech, Inc.

Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily
developing immune modulator drugs. AMZ 0026 is the company's first such drug, to
be used for the treatment of HIV/AIDS. The company intends to initiate Phase
I/II clinical studies of AMZ 0026 shortly, with an eventual goal of a joint
venture with a major pharmaceutical company in Phase III trials, or to seek to
qualify for the FDA Fast Track program to market. Amazon Biotech specializes in
natural plant pharmaceutical drugs and is focused on bringing healthier
pharmaceutical drugs to market. Additional information on Amazon Biotech may be
found at http://www.amazonbiotech.com.



Forward-Looking Statements

"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of
1995. This press release contains forward-looking information within the meaning
of Section 21E of the Securities Exchange Act of 1934, including statements
regarding any potential sales of products as well as statements that include the
words "believes," "expects," "anticipates," or similar expressions. Such
forward-looking statements involve known and unknown risks, uncertainties and
other factors that may cause the actual results, performance or achievements of
Amazon Biotech, to differ materially from those implied or expressed by such
forward-looking statements. Such factors include, among others, the risk factors
included in Amazon Biotech's reports filed with the Securities and Exchange
Commission under the Exchange Act. This press release speaks as of the date
first set forth above and Amazon Biotech assumes no responsibility to update the
information included herein for events occurring after the date hereof.

You may register to receive Amazon Biotech's future press releases and to be
added to the Company's distribution list by visiting:
http://www.roiny.com/form.php.

     Investor Relations Contact:
     Andrea Costa                     Robert Giordano
     ROI Group Associates, Inc.       ROI Group Associates, Inc.
     Phone: (212) 495-0200 x14        Phone: (212) 495-0200 x10
     Fax: (212) 495-0746              Fax: (212) 495-0746
     acosta@roiny.com                 rgiordano@roiny.com

     http://www.roiny.com